sec filing
AP
NASDAQ · APVO
Aptevo Therapeutics Inc.
Healthcare · Biotechnology
$3.50
Down-$0.10 (-2.86%)
Updated Aug 14, 2026, 12:11 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.03M
- P/E ratio
- -0.06
- Dividend yield
- 0.00%
- 52-week range
- $3.50 – $6.74
- Volume
- 148.34K
- Avg. volume
- 182.09K
Price performance
APVO price history
1M range · 20 trading sessions · Daily adjusted prices
APVO closed at $3.50 after 20 trading sessions, down 22.22% for the selected period.
- Last close
- $3.50
- Period change
- -22.22%
- Period low
- $3.50
- Period high
- $4.76
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $4.02 | $4.02 | $3.50 | $3.50 | 148.34K |
| Aug 11, 2026 | $4.0802 | $4.155 | $4.01 | $4.136 | 5.12K |
| Aug 10, 2026 | $4.1128 | $4.18 | $4.02 | $4.02 | 14.58K |
| Aug 7, 2026 | $4.12 | $4.20 | $4.10 | $4.18 | 10.35K |
| Aug 6, 2026 | $4.1086 | $4.11 | $3.96 | $4.07 | 25.08K |
| Aug 5, 2026 | $4.1135 | $4.19 | $4.01 | $4.19 | 3.78K |
| Aug 4, 2026 | $3.95 | $4.18 | $3.95 | $4.09 | 8.51K |
| Aug 3, 2026 | $4.08 | $4.08 | $3.90 | $3.95 | 11.85K |
| Jul 31, 2026 | $4.07 | $4.11 | $4.07 | $4.11 | 10.34K |
| Jul 30, 2026 | $4.085 | $4.21 | $3.90 | $4.13 | 11.19K |
| Jul 29, 2026 | $4.20 | $4.215 | $3.94 | $3.98 | 23.18K |
| Jul 28, 2026 | $4.21 | $4.3399 | $4.17 | $4.21 | 7.91K |
| Jul 27, 2026 | $4.38 | $4.45 | $4.1684 | $4.21 | 38.01K |
| Jul 24, 2026 | $4.3017 | $4.42 | $4.2813 | $4.39 | 2.54K |
| Jul 23, 2026 | $4.37 | $4.58 | $4.35 | $4.37 | 18.6K |
| Jul 22, 2026 | $4.42 | $4.5216 | $4.36 | $4.45 | 18.48K |
| Jul 21, 2026 | $4.61 | $4.61 | $4.38 | $4.42 | 26.58K |
| Jul 20, 2026 | $4.86 | $4.86 | $4.6028 | $4.755 | 26.46K |
| Jul 17, 2026 | $4.34 | $4.90 | $4.26 | $4.74 | 33.27K |
| Jul 16, 2026 | $4.49 | $4.5799 | $4.40 | $4.50 | 25.12K |
Latest APVO news
The latest Smart Investors Daily articles mentioning APVO.
Stock researchMarket Activity · Short Interest
Loading stock research…